The push for regionalized supply chains is having an impact on the CDMO landscape, with responsiveness and flexibility now considered equally important as efficiency and scale, notes Andrea Oro from ESTEVE CDMO.

The company will exhibit three key pharmaceutical processing systems for oral solid dose production at the show in New York to highlight its advances in continuous manufacturing, tablet coating, and particle processing.

As global volatility exposes the fragility of lean supply models, the industry is pivoting toward regionalized manufacturing and agile optionality to safeguard patient access.

In the current market, drug developers need to carefully balance sudden regulatory mandates with innovation while also managing costs and time efficiency, explains Meeta Kratz from Lonza Capsugel.

The new service, which is available at Lonza’s Singapore site, aims to help bioprocessing customers improve scalability, reduce manufacturing risk, and accelerate development timelines.

Aptar Pharma has entered into a technical collaboration with COVIRIX Medical to evaluate its handheld dry powder inhaler device with broad‑spectrum antiviral compounds for high‑risk respiratory viruses.

As cost pressures for drug developers persist, there is an inevitability that the industry will transition to continuous processes to overcome the limitations of traditional batch fed manufacturing.

Driven by regulatory evolution and a commitment to sustainability, the excipients’ sector is reinforcing its position as a sophisticated and credible stakeholder in the modern pharmaceutical supply chain.

Plans for a further 3,000-square-metre spray drying and high-potency containment unit at Celrà facility in Girona, Spain, have been announced by the CDMO.

The company will add new reactor suites to its Delaware campus, increasing its API reactor capacity by more than double and enabling the company to meet new demand for high-quality domestic manufacturing.

With major therapeutic indications close on the horizon, the industry must urgently address the prohibitive costs and manufacturing complexities currently blocking patient access to life-changing cures.

To secure the long-term continuity of global supply there needs to be a convergence of operational excellence and advanced chemistry, note Almac’s James Hurst and Prof. Tom Moody.

According to Maja Pedersen from FUJIFILM Biotechnologies, modularity, AI-driven compliance, and harmonized global networks are necessary to resolve complexity challenges in downstream processing.

San Diego-based Trenchant BioSystems has partnered with engineering firm Invetech to develop a fully automated manufacturing platform it claims could cut production costs by up to 80%.

The German contract manufacturer is expanding its lyophilization capacity with a complete production line from equipment supplier Syntegon, as demand for sterile freeze-dried pharmaceuticals continues to grow across the sector.

In this brief guide to DCAT Week 2026, The Pharma Navigator explores some of the critical dialogues’ attendees can look forward to participating in during their stay in Manhattan.

As sponsors navigate the complexities of a global supply environment, partnering with CDMOs who can anticipate issues and optimize processes is essential to avoid unnecessary cost hurdles, notes Kent Payne from Wilmington PharmaTech.

According to Carrie Bracco from Novartis Contract Manufacturing, by leveraging large-scale infrastructure, embedded CMOs can help meet rising demand for localized manufacturing.

Phase I trial results for the company’s novel long-acting amylin analog, have demonstrated significant potential for patients to lose up to 9.79% of body weight in 12–13 weeks with no serious adverse events.

Under this new arrangement, the companies will work together to further develop Indomo’s DT-001 candidate, which will be combined with the ClearPen device to allow self-treatment of inflammatory acne lesions.